microRNA 490-3P enhances the drug-resistance of human ovarian cancer cells by Shuo Chen et al.
Chen et al. Journal of Ovarian Research 2014, 7:84
http://www.ovarianresearch.com/content/7/1/84RESEARCH Open AccessmicroRNA 490-3P enhances the drug-resistance
of human ovarian cancer cells
Shuo Chen1, Xi Chen1, Yin-Ling Xiu1, Kai-Xuan Sun1, Zhi-Hong Zong2 and Yang Zhao1*Abstract
Background: MicroRNAs (miRNAs) are non-coding, single-stranded small RNAs that regulate gene expression
negatively, which is involved in fundamental cellular processes. In this study, we investigated the role of miR-490-3P
in the development of drug resistance in ovarian cancer cells.
Methods: The human ovarian carcinoma cell line A2780 and A2780/Taxol were exposed to paclitaxel in the
presence or absence of microRNA 490-3P transfection, after which cell viability were performed by CCK-8 assay.
Reverse transcription polymerase chain reaction (RT-PCR) and western blotting were used to assess the mRNA
and protein expression levels of GST-π, MDR1 or P-gp.
Results: Our results showed higher miR-490-3P mRNA expression level in A2780/Taxol cells than in A2780 cells
(p < 0.05). Following miR-490-3P transfection, both A2780 and A2780/Taxol cells showed decreased sensitivity to
paclitaxel. The mRNA expression levels of MDR1, GST-π (p < 0.05) and protein expression levels of P-gp, GST-π
were down-regulated after miR-490-3P transfection in comparison to mock and negative control cancer cells.
Conclusion: Our results demonstrate for the first time that microRNA 490-3P may be involved in the development
of drug resistance in ovarian cancer.
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Ovarian cancer remains the most common cause of
death from gynecological malignancies [1,2]. Among
them, epithelial ovarian cancer (EOC) is the fifth lead-
ing cause of cancer death in women and the most lethal
gynecologic malignancy in the world [3]. Given that
recurrence and metastasis seriously affect the prognosis
of ovarian cancer, the five-year survival rate for all stages
of ovarian cancer has been estimated to be 35–38% [3,4].
Primary treatment of ovarian cancer is surgical resection
of visible disease followed by adjuvant chemotherapy,
paclitaxel, for example, is commonly used in the treat-
ment of several types of cancer, including ovarian cancer.
Paclitaxel primarily kills cancer cells via microtubule
stabilization [5]. However, since numerous patients with
ovarian cancer who initially respond to paclitaxel-therapy
eventually relapse with a drug-resistant form of the dis-
ease, their five-year survival rate was not improved. Thus,* Correspondence: yida.zhaoyang@163.com
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biomarkers used as therapeutic targets for human EOC,
which also become the focus of recent research.
MicroRNAs (miRs) are small non-coding RNA molecules
18-25 nucleotides in length, which negatively regulate gene
expression at the post-transcriptional level by binding to
imperfect complementary sites in the 3’-UTR (untranslated
region) of their target messenger RNA transcripts [6].
Accumulating studies had showed that the discrepancy of
microRNA expression may contribute to cell proliferation
[7-9] and tumor development [10-14]. Thus microRNAs
have been turned out to be promising diagnostic and
prognostic molecular biomarkers as well as therapeutic
targets in cancers [15,16]. In recent years, more attention
has been paid to the role of miRNAs in reversing drug
resistance. Studies showed that microRNAs can play an
important role in modulating the sensitivity of cancer cells
to chemotherapeutic agents [17,18]. However, Zhimin Li
et al. reported that MiR-27a may up-regualte MDR1/P-
glycoprotein expression by targeting HIPK2 in human
ovarian cancer cells [19], Li H et al. also reported thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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resistance and the regulation of PDCD4 expression [20].
Until now, miR-490-3P has been validated to act as a
regulator of cell proliferation, migration, invasion, or in
the EMT in hepatocellular carcinoma cells and vascular
smooth muscle cells [21,22], but its function in ovarian
cancer cell lines has not been reported yet. This is the
first study to determine the drug-resistance function of
miR-490-3P in the ovarian cancer cell lines.
Materials and methods
Reagents
The miRNA 490-3P mimic with the sense strand sequence
5’-CAA CCU GGA GGA CUC CAU GCU G-3’ and the
control (designated Mock) sense strand sequence 5’-ACU
ACU GAG UGA CAG UAG A-3’ were used in transient
transfection of ovarian carcinoma cell lines.
Cell culture
Ovarian carcinoma cell lines, A2780 (serous cystic adeno-
carcinoma) and Paclitaxel-resistant A2780 (A2780/Taxol,
supplemented with 800 ng mL−1 Paclitaxel), were pur-
chased from ATCC. Cells were maintained in RPMI 1640
(A2780/Taxol) and DMEM (A2780) medium supplemented
with 10% fetal bovine serum, 100 units mL−1 penicillin and
100 μg mL−1 streptomycin. Cell lines were kept in a
humidified atmosphere of 5% CO2 at 37°C with or without
paclitaxel treatment and miR-490-3P transfection.
Cell viability assay
Cell Counting Kit-8 (CCK-8, Japan) was employed to
determine the number of viable cells via a colorimetric
assay. Briefly, 2.5 × 103 cells/well were seeded to a 96-well
plate and allowed to adhere. At different time points, 10
μL of CCK-8 solution was added into each well of the
plate and the plate was subsequently incubated for 3 h at
37°C prior to recording of the optical density at 450 nm.
Real-time reverse transcription polymerase chain reaction
(real-time RT-PCR)
Total RNA was extracted from the ovarian carcinoma
cell lines using TRIzol® (Takara, Kyoto, Japan). Real-time
RT-PCR was performed from 2 μg of total RNA using
AMV reverse transcriptase and random primers (Takara,
Kyoto, Japan). PCR primers were designed according to
the sequences in GenBank and are listed in Additional
file 1: Table S1. Amplification of cDNA was performed
according to the manufacturer’s protocol using an SYBR
Premix Ex Taq II kit (Takara, Kyoto, Japan) and GAPDH
as an internal control. Briefly, RT-PCR amplification of
cDNA for each primer was carried out in a final volume
of 20 μL, containing 10 μL SYBR Premix Ex Taq (×2),
0.08 μL primers, 0.4 μL ROX reference dye and 1 μL
template cDNA (50 μg μL−1). The protocol parameterswere as follows: initial incubation at 95°C for 30 s
followed by 40 cycles of denaturation at 95°C for 5 s and
annealing at 60°C for 34 s. All the PCR experiments were
accompanied with a no-template control and GAPDH as
an internal control. The relative gene expression level (the
amount of target normalized to the endogenous control
gene) was calculated using the comparative CT method:
2-ΔΔCt. The sequences of primers for real-time quantitative
PCR are supplied in Additional file 1: Table S1.
Western blot analysis
Protein assays were performed according to the Bradford
method using the Bio-Rad protein assay kit (Bio-Rad,
Hercules, CA, USA). Denatured proteins were separated
by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) on 12% acrylamide gels, and then
transferred to Hybond™ membranes (Amersham, Germany).
The membranes were blocked overnight in 5% skimmed
milk in Tris-buffered saline with Tween® 20 (TBST; 10 mM
Tris-HCl, 150 mM NaCl, 0.1% Tween® 20). For immuno-
blotting, the membranes were incubated for 1 h with the
P-gp (P-glycoprotein, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and GST-π (Abcam, Cambridge, UK)
antibody, rinsed with TBST and incubated with anti-goat
IgG antibodies conjugated to horseradish peroxidase (HRP;
Dako, Carpinteria CA, USA) at a dilution of 1:1000. After
applying electrochemiluminescent (ECL)-Plus detection
reagents (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), the protein bands were visualized using an X-ray
film (Fujifilm, Tokyo, Japan). The immunoblots were
washed with western blotting (WB) stripping buffer
(pH 2–3; Nacalai, Tokyo, Japan) and probed using a
monoclonal antibody specific for GAPDH (1:1000; Pro-
teintech Group, Chicago, USA).
Statistical analysis
Statistical evaluation was performed using Spearman’s
rank correlation coefficient to analyze ranked data, and
the Mann–Whitney U test to differentiate the means of
different groups. A p-value of <0.05 was considered statis-
tically significant. SPSS v. 10.0 software (SPSS, Chicago,
IL, USA) was employed to analyze all data.
Results
miR-490-3P decreased sensitivity of the A2780 and
A2780/Taxol cells to paclitaxel
RT-PCR results showed that A2780/Taxol has higher miR-
490-3P mRNA expression level than A2780 (Figure 1A,
p < 0.05). Figure 1B showed that the sensitivity of A2780
cells transfected with miR-490-3P mimics to paclitaxel
was decreased compared with negative control cells or
mock transfected cells, the same results was with A2780/
Taxol. Besides, A2780/Taxol shows greater resistance to
paclitaxel than A2780.
Figure 1 miR-490-3P decreased sensitivity of the A2780 and
A2780/Taxol cells to paclitaxel. RT-PCR results showed that
A2780/Taxol has higher miR-490-3P mRNA expression level than
A2780 (A). CCK-8 cell proliferation assays show that after miR-490-3P
transfection, the sensitivity of both A2780 and A2780/Taxol cells
transfected with miR-490-3P mimics to paclitaxel was decreased
compared with that treated with NC or Mock cells (B). Results are
representative of three separate experiments; data are expressed as
the mean ± standard deviation.
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RT-PCR results showed that after transfected with mimics
of microRNA 490-3P, the mRNA expression levels of
MDR1 and GST-π in A2780 and A2780/Taxol cell lines
were higher than those observed in negative control cellsor mock transfected cells (Figure 2A, p < 0.05). At the
same time, western blot analysis of the protein expression
levels of P-gp and GST-π were also higher than those
of negative control cells and mock transfected cells
(Figure 2B).
Discussion
Accumulating evidence nowadays revealed that aberrant
microRNA expression is strongly implicated in the
development of drug resistance. They may affect the
expression of target proteins which could be drug
transporters, drug targets or cell apoptosis and cell-cycle-
related components, resulting in variations of sensitivity of
cells to chemo-therapeutic drugs. Studies showed that
miR-21, 106a, 27a, 487, for example, may be involved in
the development of drug resistance through regulating
relative gene expression [17-20,23]. The studies about the
roles of miRNAs in the development of drug resistance
have attracted much attention nowadays.
Studies reveal that miR-490-3P overexpression leads to
inhibition of cell proliferation via G1-phase arrest. Gu
et al. reported that miR-490-3p inhibits proliferation of
A549 lung cancer cells [24], and Zhang et al. showed
that miR-490-3p modulates cell growth and epithelial to
mesenchymal transition (EMT) of hepatocellular carcin-
oma cells [21]. These studies suggest us that miR-490-3P
may also contribute to tumor development; however, its
function in the development of drug resistance hasn’t
been studied.
Our RT-PCR results showed that A2780/Taxol has
higher miR-490-3P mRNA expression level than A2780.
To investigate whether miR-490-3P could modulate the
sensitivity to paclitaxel, we transfected A2780/Taxol and
A2780 cells with mimics of miR-490-3P respectively, and
then the cells were treated with a series of concentrations
of paclitaxel. Our results showed that the sensitivity of
both A2780 and A2780/Taxol cell lines transfected with
miR-490-3P mimics to paclitaxel was decreased compared
with negative control or mock cells, suggesting that
microRNA 490-3P may be involved in the development
of drug resistance in ovarian cancer cells.
Multidrug resistance (MDR) is one of the major reasons
chemotherapy-based treatments fail. Of the many mecha-
nisms of MDR, the high expression of the human MDR1
gene and the P-glycoprotein (P-gp) transporter encoded
by MDR1 is an important focus of research [25]. Tumor
cells that overexpress MDR1/P-gp usually show resistance
to various chemotherapeutics [26]. Previous studies on the
efflux pump have shown that P-gp plays an important
part, as it pumps drug substance outside to reduce
cytotoxicity presented by cancer cells and enhances the
resistance of carcinoma to chemotherapeutics. The drug
resistance presented by cancer cells can be effectively
induced by up-regulating P-gp expression and function
Figure 2 miR-490-3P down-regulate MDR1/P-gp and GST-π expression. RT-PCR results showed that after microRNA 490-3P transfection, the
mRNA expression levels of MDR1 and GST-π in A2780 and A2780/Taxol cell lines were higher than negative control cells or mock cells (A, p < 0.05).
Western blot analysis showed that the protein expression levels of P-gp and GST-π were also higher than those of negative control cells and mock cells
(B, p < 0.05).
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glutathione S-transferase), one of the members of the
glutathione S-transferase (GST) family, is responsible for
excessive intensity of detoxification of cytostatics, and have
been shown to have functional polymorphisms that may
affect drug metabolism and influence the effects of chemo-
therapy and survival from cancer [30]. Beeghly A et al.
showed that reduced GST function may improve ovariancancer survival after post-operative chemotherapy; evalu-
ation of GST functional polymorphisms may help to pre-
dict ovarian cancer prognosis [31].
Our RT-PCR results showed that after transfected with
mimics of microRNA 490-3P, the mRNA expression
levels of MDR1 and GST-π in A2780 and A2780/Taxol
cell lines were higher than those observed in negative
control cells or mock transfected cells. At the same time,
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levels of P-gp and GST-π were also higher than those of
negative control cells and mock transfected cells, thus,
we suggest that microRNA 490-3P may be involved in
the development of drug resistance through regulating
MDR1/P-gp and GST-π expression in ovarian cancer cells.
Above all, we suggest that when microRNA 490-3P was
used to reduce ovarian carcinoma’s recurrence, invasion
and metastasis, it’s better not to choose paclitaxel for
chemotherapy, and we must pay attention to the impact
of microRNA 490-3P when using chemotherapy drugs for
clinical treatment, drug trials must be conducted.
In conclusion, we demonstrated for the first time that
microRNA 490-3P may be involved in the development
of drug resistance in ovarian cancer cells. The aberrant
specific molecular mechanisms need further study and
its clinical manipulation also needs to be cautiously
considered in future work.
Conclusions
We demonstrated for the first time that miR-490-3P may
be involved in the development of drug resistance in ovar-
ian cancer cells. The aberrant specific molecular mecha-
nisms need further study and its clinical manipulation also
needs to be cautiously considered in future work.
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